Weight Gain at Midlife Isn't a Willpower Problem. Here's What's Actually Happening.
Seventy percent of women gain weight during the menopause transition. The average is about a pound and a half per year — and when the full transition spans a decade, that adds up to fifteen to twenty pounds that most women were never told to expect. They were also rarely told why or that anything beyond “eat less and move more” was available to help.
This HERtalks session was built to change that. Dr. Angela Fitch — past president of the Obesity Medicine Association, co-founder and Chief Medical Officer of Knownwell, and one of the country’s leading voices in obesity medicine — brought the data, the nuance, and a framework for thinking about midlife weight that most clinicians never have time to explain.
The First Thing to Understand: This Is a Disease, Not a Character Flaw
Dr. Fitch opened by naming something most weight conversations skip entirely: obesity is a serious, treatable chronic disease — not a failure of willpower, discipline, or effort. It is multifactorial, driven by genetics, epigenetics, environment, hormones, immune function, and neurobiology. The decision to eat, how much, and when is regulated by a complex interplay of systems that have nothing to do with motivation.
This reframe matters because the way we think about the problem determines what solutions we’re willing to consider. If midlife weight gain is a willpower problem, the answer is to try harder. If it’s a physiological one, the answer looks completely different.
What’s Actually Driving Weight Gain at Midlife
Dr. Fitch described what she called the triple whammy of the menopause transition — three simultaneous forces working against the body at once. Understanding each one explains why women who haven’t changed anything about their habits suddenly see their body composition shifting.
The details of how these three forces interact and what that means for your treatment approach are in the full session. What’s worth knowing going in is that all three are real, measurable, and responsive to intervention.
The Metabolism Myth
One of the session’s sharpest moments was Dr. Fitch addressing the most common thing women believe about midlife weight gain: that their metabolism is slowing down.
The research — and she cited it specifically — tells a more nuanced story. Total energy expenditure stays relatively flat across much of the adult lifespan. The more important variable is muscle mass. And that changes things considerably in terms of where to focus.
Sleep Is Doing More Work Than You Think
Dr. Fitch spent meaningful time on sleep — not as a general wellness recommendation, but as a direct driver of where the body stores fat. The connection between sleep quality and abdominal fat accumulation is specific, it’s measurable, and it’s one of the most actionable levers available during this transition. If sleep is disrupted — whether from vasomotor symptoms, bladder issues, or anything else — addressing it directly is part of managing weight, not separate from it.
Leaner, Not Lighter
One of the session’s most useful reframes was Dr. Fitch’s insistence on dropping weight as the primary goal in favor of body composition. The number on the scale is not the point. The relationship between fat mass and muscle mass is.
“We want to be leaner, not lighter.” — Angela Fitch, MD
This isn’t a semantic distinction. It changes what you measure, what you prioritize, and what counts as progress. The recording goes into what that actually looks like in practice — including Dr. Fitch’s five-part framework for approaching nutrition during this phase.
What the Treatment Data Actually Shows
The treatment efficacy data Dr. Fitch presented are striking enough to warrant sharing directly, as they reframe what’s possible and why certain options have generated so much attention.
With lifestyle intervention alone—diet, exercise, and tracking —roughly 10% of people achieve a meaningful level of weight loss. That’s not a judgment on effort. That’s the biology. With the addition of medication, that number changes substantially. And the gap between the best lifestyle-only outcomes and the best medication-assisted outcomes is wider than most people realize.
Dr. Fitch walked through where GLP-1 medications fit in that picture, how they work on multiple systems simultaneously, and how they differ from older weight management medications. The session also covers what questions to bring to a clinician and what realistic expectations look like — including the 4% of people who don’t respond.
On Compounded GLP-1s
Dr. Fitch addressed compounded semaglutide and tirzepatide directly, and the message was clear: compounded versions are not the same product as the branded medications, and the professional organizations representing obesity medicine do not recommend them.
The core issue is manufacturing. There is no generic semaglutide or tirzepatide. The branded medications were brought to market through clinical trials involving tens of thousands of patients. Compounded versions are made without the same process, standards, or safety data. Potential impurities in the molecule are a documented concern.
If you’ve been offered a compounded GLP-1 or been tempted by the lower price point, the full session covers what to ask and what to know before making that decision.
Access the Full Recording
The full session — including Dr. Fitch’s complete presentation, her five-part nutrition framework, and a Q&A covering topics from microdosing to breast cancer survivorship to what happens when a medication stops working — is available to HERmedicine members.
Frequently Asked Questions
Why do women gain weight during menopause?
Menopause-related weight gain is driven by hormonal shifts, changes in body composition, and changes in how the body stores fat — particularly an increase in visceral, or belly, fat. It’s not caused by eating more or moving less. Seventy percent of women experience weight gain during the menopause transition, averaging about one and a half pounds per year.
Does metabolism slow down during menopause?
Less dramatically than most people believe. Research shows that total energy expenditure stays relatively flat across much of the adult lifespan. The bigger variable is muscle mass — the more muscle you have, the more calories you burn at rest. Menopause accelerates muscle loss, which is why resistance training becomes especially important during this phase.
Are GLP-1 medications like Ozempic or Wegovy safe for women at midlife?
The longest randomized controlled trial of these medications ran for four years and showed no increase in serious adverse events. They are FDA-approved for specific indications — a BMI of 30 or above, or 27 or above with a qualifying condition. Side effects, including nausea, constipation, and GI changes, are real and manageable. They are not appropriate for everyone, and prescribing should be based on a thorough clinical evaluation.
Is compounded semaglutide the same as Ozempic or Wegovy?
No. There is no generic semaglutide. Compounded versions are not manufactured to the same standards as branded medications, have not been through the same clinical trials, and may contain impurities. The Obesity Medicine Association, the Obesity Society, and the American Diabetes Association do not recommend compounded GLP-1 medications.
Can lifestyle changes alone address midlife weight gain?
Lifestyle changes are essential and are part of any effective approach — but the data shows that roughly 10% of people achieve significant weight loss through lifestyle intervention alone. That’s not a willpower failure. It reflects the biology underlying the body's resistance to weight loss. For many women, additional interventions are not a shortcut — they’re appropriate medical treatment.
About the Speakers
Angela Fitch, MD, FACP, FOMA
Angela Fitch, MD, FACP, FOMA, is a board-certified internist and obesity medicine specialist, co-founder and Chief Medical Officer of Knownwell — a patient-centered medical home for metabolic health and weight management — and past president of the Obesity Medicine Association. She is also a board member of the Obesity Action Coalition, the patient advocacy organization for people with weight management concerns. With 25 years in obesity medicine and active involvement in clinical research and national standards of care, Dr. Fitch is one of the country’s leading voices on evidence-based weight management across the lifespan.
Dr. Lisa Larkin, MD, FACP, MSCP, IF — Moderator
Dr. Lisa Larkin, MD, FACP, MSCP, IF, moderated the discussion. As founder of HERmedicine and Ms.Medicine, Dr. Larkin is a national leader in personalized, evidence-based women’s preventive health and hormonal care.
